spacer
home > ebr > summer 2018 > driving discovery
PUBLICATIONS
European Biopharmaceutical Review

Driving Discovery

EBR: What are the benefits of mass spectrometry (MS) as an analytical method?

Simon Cubbon: MS, from its early beginnings through to its current use, has seen an ever-increasing adoption; this is because of the large amounts of information, resulting in quality and, therefore, confidence that this technique can provide, ultimately, safeguarding end-users.

Additionally, both high- and low-resolution systems are becoming increasingly simpler to use; this, combined with the intricacy of products being brought to market (eg protein-based therapeutics, such as monoclonal antibodies or antibodydrug conjugates), requires techniques that can provide the necessary structural insights needed to fully characterise and understand these complexities.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Simon Cubbon works as a pharma and biopharmaceutical Vertical Marketing Manager at Thermo Fisher Scientific. He has worked within the analytical instruments industry for over 10 years, holding a variety of positions from applications scientist through to informatics product management. Simon studied for his PhD at the University of York, UK, where he was interested in using LC-MS to study the metabolic profile of long bone fractures.
spacer
Dr Simon Cubbon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CBIs Global Risk Based Monitoring Event

CBIs Global Risk Based Monitoring Event is approaching, taking place in London on 13 14 September 2018, designed for benchmarking with international peers to gauge RBM performance, efficiencies, implementation and technologies.
More info >>

White Papers

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

Temptime Corporation

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
More info >>

 
Industry Events

Clinical Trial Supply Southeast 2018

2-3 October 2018, Cary, North Carolina

Clinical Trial Supply Southeast will return to Cary, North Carolina for fall 2018. Part of our global series of events, this show will attract the leading biotech and pharma companies from the Southeast region, the event will focus on how companies can adapt their supply chains to fit into the highly regulated world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement